Achaogen to Participate in the Leerink Partners 6th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be participating in the Leerink Partners 6^th Annual Global Healthcare Conference, taking place February 15–16, 2017, at the Lotte New York Palace Hotel, New York, NY. Achaogen management will present at 2:30 p.m. Eastern Time on Thursday, February 16^th, 2017.

A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived for 30 days following the conference for those unable to listen live.

About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.

Investor Contact: 	
Hans Vitzthum		
212.915.2568		
[email protected]

Media Contact:
Denise Powell
510.703.9491
[email protected]

Source:  Achaogen, Inc. (AKAO).